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Abstract 
 
The HOX genes are a family of closely related transcription factors that help to define the identity of cells 
and tissues during embryonic development and which are also frequently deregulated in a number of 
malignancies, including breast cancer. Whilst relatively little is known about the roles that individual HOX 
genes play in cancer, it is however clear that these roles can be both contradictory, with some members 
acting as oncogenes and some as tumor suppressors, and also redundant, with several genes essentially 
having the same function. Here we have attempted to address this complexity by using the HXR9 peptide 
to target the interaction between HOX proteins and PBX, a second transcription factor that serves as a 
common co-factor for many HOX proteins. We show that HXR9 causes apoptosis in a number of breast 
cancer-derived cell lines and that sensitivity to HXR9 is directly related to the averaged expression of HOX 
genes HOXB1 through to HOXB9, providing a potential biomarker to predict the sensitivity of breast 
tumors to HXR9 or its derivatives. Measuring the expression of HOX genes HOXB1 to HOXB9 in primary 
tumors revealed that a subset of tumors show highly elevated expression indicating that these might be 
potentially very sensitive to killing by HXR9. Furthermore, we show that whilst HXR9 blocks the 
oncogenic activity of HOX genes, it does not affect the known tumor-suppressor properties of a subset of 
HOX genes in breast cancer. 
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Introduction 
 
The HOX genes are a family of homeodomain-containing transcription factors that were first identified as 
determinates of cell and tissue identity in early development, although they are now also known to function 
in adult stem cell renewal and differentiation [1-3]. A series of duplication events is thought to have given 
rise to the four separate clusters of HOX genes found in vertebrates, with each cluster consisting of a group 
of closely linked members that often share enhancer regions. These clusters are named A, B, C and D, and 
together they contain the 39 HOX genes found in mammals[4]. Each gene within a cluster is labeled with a 
number according to their relative position in the chromosome, so for example HOXB1 is the 3’ most 
member of the B cluster, and HOXB13 is the 5’ most member[5]. The linkage of genes within each cluster 
is closely reflected in both their temporal and spatial order of expression in the embryo, with the 3’ genes 
being expressed more anteriorly and earlier than their 5’ neighbors. The relative position within the cluster 
is also reflected in the co-factor interactions, DNA binding specificity and regulation of each member[4].  
 
In addition to a role in development, and subsequently in stem cell differentiation, the HOX genes are also 
frequently deregulated in a number of cancers including melanoma, mesothelioma, and lung, kidney, 
prostate, ovarian and breast cancer[6]. Their function in oncogenesis is still unclear; however it is apparent 
that the great complexity of HOX function in development is also reflected in oncogenesis, with some HOX 
genes functioning as tumor suppressors and others as oncogenes. The best known examples of both have 
been identified in breast cancer, where HOXA5 is known to function as a tumor suppressor[7], at least in 
part through activating the transcription of the key tumor suppressor gene TP53[8]. Conversely, members 
of the closely related HOXB genes including HOXB5 and HOXB7 are oncogenic through mechanisms 
which include an up regulation of FGF2[9], and the promotion of epithelial to mesenchymal transition[10]. 
HOXB7 has also been shown to confer tamoxifen resistance through activation of the EGFR pathway[11]. 
Exactly how such similar transcription factors can have opposing functions is also unclear, although it may 
be related to differential co-factor binding and consequently differential regulation of target genes. Known 
co-factors include members of the PBX, MEIS and PREP families of transcription factors all of which can 
influence the binding selectivity of HOX proteins and their action as either a suppressor or activator of 
 4
transcription[3]. As an additional complexity, HOX proteins can also regulate transcription through binding 
to DNA as monomers[12]. 
 
Whilst different HOX genes can have individual, specific functions in embryonic development, there is 
generally a high level of functional redundancy, especially with regards to fundamental and highly 
conserved patterning events such as anterior-posterior pattering of the spine and hindbrain[13, 14]. This is 
also true in cancer, where a similar oncogenic function is common to a number of HOX genes, especially 
HOXB1 through to HOXB9[14, 15].  
 
This mixture of opposing functionality and functional redundancy, combined with the lack of ligand 
binding sites, makes targeting HOX genes in cancer potentially very difficult. One approach however is to 
target multiple groups of HOX genes in a way that also singles out specific HOX functions, something that 
could potentially be achieved by disrupting the binding of HOX proteins to specific co-factors. To date this 
has only been possible for the PBX co-factor that can bind to HOX proteins numbered 1 to 9[15-19]. PBX 
increases the nuclear translocation of HOX proteins and also influences the selection of DNA binding 
sites[20, 21]. Its interaction with HOX is mediated by a highly conserved hexapeptide region on HOX 
proteins[20-23] and previous studies have shown that a synthetic peptide consisting of these amino acids 
and a short polyarginine sequence, known as HXR9, is capable of blocking the interaction between HOX 
and PBX proteins both in vitro and in vivo. HXR9 causes apoptosis in a number of cancers including 
melanoma[15], myeloma[18], and kidney[16], non-small cell lung[17], and ovarian cancer[19]. Here we 
show that HXR9 also causes apoptosis in cell lines derived from different breast cancers, and that HXR9 
specifically blocks the oncogenic function of HOX genes without blocking the known tumor-suppressor 
role of HOXA5. Importantly, we also show that there is an extremely high correlation between the average 
expression of HOX genes HOXB1 through HOXB9 and the sensitivity of cell killing by HXR9. 
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Materials and Methods 
 
Cell lines and culture 
The cell lines used in this study are listed in Supplementary Table 1. They were obtained from the ATCC 
through LGC Standards Ltd (UK), and were cultured according to the instructions on the LGC Standards 
website. 
 
Synthesis of HXR9 and CXR9 peptides 
HXR9 is an 18 amino acid peptide consisting of the previously identified hexapeptide sequence that can 
bind to PBX and nine C-terminal arginine residues (R9) that facilitate cell entry[15]. The N-terminal and C-
terminal amino bonds are in the D-isomer conformation, which has previously been shown to extend the 
half life of the peptide to 12 hours in human serum[15]. CXR9 is a control peptide that lacks a functional 
hexapeptide sequence but which includes the R9 sequence. All peptides were synthesized using 
conventional column based chemistry and purified to at least 80% (Biosynthesis Inc, USA). 
 
Imaging of cell cultures 
Cells were plated in 6-well plates using 2 ml of medium and allowed to recover for at least 24 hours.  When 
approximately 60% confluent, cells were treated with the active peptide HXR9 (60 µM) or the control 
peptide CXR9 (60 µM) for 3 hours.  For phase contrast micrographs, the cells were washed twice with cold 
PBS and visualized using a Nikon Eclipse TS100 inverted microscope and images recorded using a Nikon 
camera and capture software (Jencons).   
 
Analysis of cell death and apoptosis 
Cells were treated with HXR9 or CXR9 as described above.  Assessment of cell viability was done using 
the MTS assay (Promega) according to the manufacturer’s instructions.  Cells were harvested by incubating 
in trypsin-EDTA (Sigma) at 37ºC until detached and dissociated.  Apoptotic cells were identified using 
flow cytometry (Beckman Coulter Epics XL Flow) and the Annexin V-PE apoptosis detection kit (BD 
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Pharmingen) as described by the manufacturer’s protocol. Caspase-3 activity was measured using the 
EnzCheck Caspase-3 Assay Kit (Molecular Probes), using the protocol defined by the manufacturer. 
 
RNA purification and reverse transcription 
Total RNA was isolated from cells using the RNeasy Plus Mini Kit (Qiagen) by following the 
manufacturer’s protocol.  The RNA was denatured by heating to 65ºC for 5 minutes.  cDNA was 
synthesized from RNA using the Cloned AMV First Strand Synthesis Kit (Invitrogen) according to the 
manufacturer’s instructions. 
 
Quantitative PCR 
Quantitative PCR was done using the Stratagene MX3005P real-time PCR machine and the Brilliant SYBR 
Green QPCR Master Mix (Stratagene).  Oligonucleotide primers were designed to facilitate the unique 
amplification of β-actin, c-Fos, TP53 and each HOX gene. 
 
Transcriptional profiling 
Total RNA was extracted from SKBR3 cells treated with CXR9 or HXR9 (60 µM) for three hours, and was 
used as a template to generate Cy3-labelled cRNA using the Low RNA Input Linear Amplification Kit 
(Agilent).  Each Cy3-cRNA was used as a probe on the Whole Human Genome Microarray (4x44K) slide.  
This microarray consists of 60-mer oligonucleotides with sequences representing more than 41,000 human 
genes.  The microarray slides were scanned and data were extracted using the Agilent Feature Extraction 
Software (version 9.5.3).  Data was analyzed using GeneSpring GX software. The full data set and further 
experimental details have been deposited in the Array Express repository; accession number E-MEXP-
3634. 
 
Mice and in vivo trial 
All animal experiments were conducted in accordance with the United Kingdom Co-ordinating Committee 
on Cancer Research (UKCCCR) guidelines for the Welfare of Animals in Experimental Neoplasia[24] and 
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were approved by the University of Surrey Research Ethics Committee. The mice were kept in positive 
pressure isolators in 12 hour light / dark cycles and food and water were available ad libitum. 
Athymic nude mice were inoculated subcutaneously with a suspension of 2.5 x 106 MDA-MB231 
cells in culture media (100 µl).  Once tumors reached volumes of approximately 100 mm3, mice received 
an initial dose of 100 mg/Kg CXR9 or HXR9 intratumorly, with subsequent dosing when or if the tumor 
reoccurred.  Each treatment group contained 10 mice. The mice were monitored carefully for signs of 
distress, including behavioral changes and weight loss.  
 
Patient samples 
Patient breast tissue samples and clinico-pathological data were obtained from the Guy’s and St Thomas’ 
(GST) Breast Tissue and Data Bank, London, UK (REC ref: 07/H0804/131).This collection has approval 
from the GST Research Ethics Committee (ref: 07/H0804/131) and adheres to the Helsinki Declaration. 
Patients had given consent for the inclusion of their tissue in this bank; individual permission from each 
patient was not subsequently required for the particular study described here. Frozen sections were cut and 
using a stained guide slide, malignant cells were dissected from the surrounding tissue. RNA was extracted 
using the AllPrep DNA/RNA Micro kit (Qiagen). The manufacturer instructions were followed with the 
exception of an enhanced homogenization step.  
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Results 
 
HOX gene expression in breast cancer cell lines and normal breast tissue 
In order to assess the expression of HOX genes in breast cancer and in normal breast tissue five breast 
cancer-derived cell lines were used, SKBR3, MB231, MCF7, ZR75.1 and UACC, together with MCF10a, 
derived from a non-malignant mammary epithelium (detailed in Online resource 4). RNA was extracted 
from cultures of each of these, together with normal breast tissue. HOX expression was determined by 
semi-quantitative PCR, and calculated as a ratio with the expression of the house keeping gene GAPDH 
(Fig 1). This reveals a significant, but variable degree of HOX deregulation between breast cancers derived 
cell lines and normal breast tissue, with normal breast tissue and the non-malignant cell line MCF10a 
generally having lower expression than the cancer derived cell lines.  
 
HXR9 is toxic to breast cancer cells 
Previous studies have indicated that HXR9 is taken up by and is selectively cytotoxic to cancer cells. A 
fluorescently labeled derivative of HXR9 was incubated with MDA-MB231 cells and localized to both the 
cytoplasm and the nucleus (Fig 2a). In order to determine the IC50 for cell killing by HXR9 we used an 
MTS assay at varying concentrations of the peptide. This indicated that the IC50 for cell killing for 
SKBR3, MDA-MB231, MCF7, ZR75.1, UACC and MCF10a were 16µM, 23µM, 33µM, 42µM, 48µM 
and 51µM, respectively. Thus MCF10a and the breast cancer derived cell lines UACC, ZR75.1 and MCF7 
are relatively insensitive to HXR9 whilst MDA-MB231 and SKBR3 are significantly more sensitive 
(p<0.01; Fig 2b). As a control a second peptide was used, CXR9, which has an identical polyarginine cell 
penetrating sequence to HXR9 but which lacks an active hexapeptide sequence. None of the cell lines were 
sensitive to CXR9 (i.e. IC50 > 100µM). 
 
Treatment with HXR9 increases the expression of cFos but not TP53 
Previous studies have shown that HOX genes can prevent apoptosis, at least in part, by blocking the 
expression of cFos, and that HXR9 can induce apoptosis by mediating a rapid increase in the number of 
cFos transcripts[15]. SKBR3 and M cells similarly show a very large increase in cFos expression (553 
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fold) two hours after HXR9 treatment (Fig 3). Conversely, some HOX genes have been identified as 
potential tumor suppressors in breast cancer. Most notable amongst these is HOXA5, which functions at 
least in part through its regulation of TP53[8].  The detailed mechanism for this regulation is yet to be 
elucidated, but if it requires a HOXA5 / PBX dimer then it might be expected that HXR9 could reduce 
TP53 expression and therefore be pro-oncogenic in this respect. In order to determine whether this is the 
case we assayed TP53 expression in SKBR3 and MDA-MB231 cells treated with HXR9 by Quantitative 
PCR. This revealed that there is no significant change in TP53 expression in response to HXR9 treatment 
in either cell line (Fig 3).  Similar changes were also found to occur at the protein level using western 
blotting (Fig 3). 
 
HXR9 primarily causes transcriptional activation 
In order to identify additional target genes that are regulated by a HOX/PBX dimer, and are thus 
differentially expressed upon treatment with HXR9, we used whole genome based microarray to study the 
transcriptome of HXR9 treated SKBR3 cells. This revealed that the majority of HXR9 target genes 
identified are upregulated by HXR9 treatment (Online resource 1), indicating that the HOX / PBX dimers 
act predominantly to repress transcription in these cells. The promoter regions of the 20 genes that are most 
strongly upregulated by HXR9 were analyzed for the presence of the HOX / PBX binding consensus[25]. 
Of these 20 genes 18 had at least one potential site, and many of the promoter regions had multiple and 
often overlapping consensus binding sites (Online resource 2), including ATF3, NR4A3, ZFP36 and 
PPP1R15A, that have tumor suppressor functions (Online resource 5). Furthermore, amongst those genes 
that were upregulated by ten fold or more, 22 have known tumor suppressor function. 
 
HXR9 induces apoptosis 
The mechanism of cell death was studied in the most sensitive of six cell lines, SKBR3. Previous studies 
have shown that HXR9 can induce apoptosis through, at least in part, a rapid increase in expression of 
cFos[15]. SKBR3 and MDA-MB231 cells similarly show a very large increases in cFos expression (553 
and 19.3 fold, respectively) two hours after HXR9 treatment (Fig 3). In order to establish whether HXR9 
induces apoptosis, HXR9 treated cells were analyzed by FACS after staining with Annexin-7AAD and 
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propidium iodide. The former allows the detection of changes in the cell membrane that are characteristic 
of apoptosis, whilst the later is used to evaluate membrane integrity (Fig 4a). This shows that HXR9 treated 
SKBR3 undergo cell death predominantly through apoptosis, with the majority of cells being in an early 
stage of apoptosis two hours after HXR9 treatment (Fig 4b). There is also a corresponding increase in 
Caspase 3 activity over two hours with the same concentration of HXR9 (Fig 4c). Similar results were 
obtained for the MDA-MB231 cell line (not shown). 
 
Sensitivity to HXR9 correlates with HOX expression 
As HXR9 targets the HOX / PBX interaction, we calculated the average expression of all HOX genes 
numbered between 1 and 9 (i.e. the 3’ most 27 members of the HOX family that bind PBX), for all of the 
cell lines and for normal breast tissue. When ranked against sensitivity to HXR9 there is an apparent 
positive relationship between mean HOX expression and IC50 with the exception of MCF7 (Fig 5a). 
However, when cell line sensitivity is ranked against mean expression of only the HOX genes HOXB1 
through to HOXB9 the ranked order is complete (Fig 5b). When mean expression of HOXB1 through 
HOXB9 is plotted against the IC50 for HXR9 toxicity a linear relationship is apparent, the line of 
regression for this putative relationship has an r2 value of 0.9778 (p=0.0002), (Fig 5c).  
 
HOX genes HOXB1 through to HOXB9 are highly expressed in a subset of primary breast tumors 
In order to explore the possible relevance of these findings to primary tumors we measured the transcripts 
of HOX genes HOXB1 through to HOXB9 in 78 primary tumor samples obtained from the GST Breast 
Tissue and Data Bank, the associated pathological characteristics of which are listed in Online resource 6.  
This revealed that whilst the majority of tumors expressed these genes to a relatively low level, a subset 
(7.4%) showed a highly elevated level of expression that could indicate that these cells would be sensitive 
to killing by HXR9 (i.e. with an IC50 <1µM, Fig 5d). High levels for HOXB1 through to HOXB9 
expression did not correlate with expression of the estrogen receptor (ER), progesterone receptor (PR), or 
HER2, nor with survival, tumor grade, or spread to axillary lymph nodes (Online resource 3). There was 
however a positive association between low HOXB1 through to HOXB9 expression and mucoid or lobular 
histology (Online resource 3). 
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HXR9 retards tumor growth in vivo 
In order to assess the efficacy of HXR9 in vivo we established a xenograft model of MDA-MB231. 
Although these cells are less sensitive to killing by HXR9 than SKBR3, it is more widely used as a 
xenograft model (605 references in PubMed compared to 35 for SKBR3), and represents a form of breast 
cancer with a poor prognosis, having been derived from a tumor negative for HER2, ER and PR[26]. 
Tumors were initiated by injection of cells into the flank, and treatment was started when the average tumor 
volume had reached 100 mm3  with an initial dose of HXR9 of 20 mg/Kg intratumorally, followed by an 
additional dose if tumor growth reoccurred (with no more than one additional dose per animal). Tumor 
growth in HXR9 treated mice was retarded 7.5 fold at 13 days compared to the control group (Fig 6a), and 
the HXR9 treated animals survived for significantly longer (88% survival at 30 days as compared to 0% for 
the control group, p=0.004; Fig 6b) RNA was extracted from tumors at the end of 32 days in order to 
measure cFos expression by QPCR; cFos was found to be expressed at an 18-fold higher level in tumors 
from HXR9 treated mice than in tumors from untreated mice (Fig 6c). Histological analysis of CXR9 and 
HXR9 treated tumors revealed extensive cell death in the later (Fig 6d). 
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Discussion 
 
In this study we have shown that HOX genes are generally deregulated in breast cancer, and mostly there is 
an increase in expression when compared to normal breast tissue or non-malignant MCF10a cells, although 
the exact pattern of expression varies between cell lines. The significance of the variation between cell lines 
is unclear, although the functional redundancy between HOX genes may mean that the net effect of HOX 
over expression is similar. There are however cases where cancer phenotype can be determined by specific 
HOX genes, for example in ovarian cancer HOXA11 expression confers a mucinous (as opposed to serous) 
phenotype[27], and distinct patterns of HOX expression are associated with lymphoblastoid myeloma[18]. 
 
We also show that treating breast cancer cell lines with the HOX / PBX inhibitor HXR9 causes apoptosis in 
SKBR3 and is cytotoxic to all of the lines tested. This suggests, as it has done in studies on other cancers, 
that targeting the HOX / PBX dimer allows a specific subset of HOX functions to be modified, one of 
which includes the repression of apoptosis[15-19]. In the case of melanoma, apoptosis is induced in part 
through the induction of cFos[15], and a large increase in cFos expression is also observed in this study 
when SKBR3 cells are treated with HXR9. Selective targeting of anti-apoptotic functions is important as 
some HOX genes, notably HOXA5 in breast cancer[8], have a tumor-suppressor role rather than an 
oncogenic role. This is at least partly mediated by an increase in TP53 expression[8], however we show 
here that HXR9 does not change TP53 expression in breast cancer cells, suggesting that the regulation of 
TP53 by HOXA5 does not depend upon a HOXA5 / PBX dimer, but may instead be dependant on other co-
factors, or may possibly not require a co-factor. The later possibility is supported by the observation that 
forced expression of HOXA5 alone is sufficient to drive TP53 transcription, and that the HOXA5 binding 
site identified in the TP53 promoter does not appear to include a PBX binding consensus[8]. Further, whilst 
confirming a positive interaction between HOXA5 and TP53, a more recent study also suggests that TP53 is 
not transcriptionally regulated by HOXA5[28]. These findings support the conclusions of previous studies 
that indicate the HOX / PBX dimers are predominantly anti-apoptotic in the context of cancer[15-19]. 
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An oncogenic role for HOX / PBX dimers is also supported by the transcriptional repression of genes with 
known tumor suppressor functions, all of which exhibit a correspondingly large increase in expression upon 
HXR9 treatment (Online resource 5). These include EGR2[29] and ATF3[30], both of which function in 
p53 mediated apoptosis, the GTPase encoding gene RRAD which is frequently lost in malignancy[31], and 
the EGFR / ERBB2 inhibitor ERRFI1[32]. These findings are of particular interest because they suggest 
potential synergistic interactions between HXR9 and other classes of drug. 
 
Identifying patients that are likely to respond to a particular treatment is a now a key requirement in clinical 
trials, and the development of predictive biomarkers for this purpose is most effective at early drug 
development stages. We hypothesized that sensitivity to HXR9 in breast cancer lines should depend, at 
least to some extent, on HOX gene expression. Given the functional redundancy found in the PBX binding 
HOX proteins, we examined whether sensitivity might depend on the averaged level of HOX gene 
expression. In fact, our results suggest that this is not the case. However, the averaged expression level of a 
subset of HOX genes, namely HOXB1 through HOXB9, does correlate with sensitivity to HXR9 with a 
highly significant line of regression. High levels of HOXB1 through HOXB9 expression are associated with 
increased sensitivity to killing by HXR9, whilst low levels of expression are associated with insensitivity to 
HXR9. Here we show that both normal breast tissue and the non-malignant mammary line MCF10a have 
relatively low levels of expression, and the later is also relatively resistant to HXR9 mediated cell killing.  
 
Conclusions 
The significance of these finding requires further study, although we note that HOXB genes have in general 
been more frequently implicated as having a role in cancer, both through direct mechanistic studies[6] and 
through a number of clinical observations including the association of elevated HOXB7 expression with a 
poor prognosis in HER2 positive breast cancer[33]. Our analysis of 78 primary breast tumors showed that 
whilst the majority had relatively low levels of HOXB1 through to HOXB9 expression, a subset had very 
highly elevated expression of these genes, indicating that they could potentially be extremely sensitive to 
HXR9. Determining the expression of these genes from biopsies could form the basis by which patients 
might be selected for treatment by HXR9, or its derivative.  
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Figure Captions 
 
Fig. 1 HOX gene expression in breast cancer derived cell lines and in normal breast tissue. The 
expression of each gene was determined by semi-quantitative PCR and is shown relative to the house 
keeping gene GAPDH (x10000). The values shown are the mean of three independent experiments and the 
error bars represent the SEM. NBT – normal breast tissue. 
 
Fig. 2 (a) HXR9 enters the cytoplasm and nuclei of MDA-MB231 cells in vitro. MDA-MB231 cells 
were incubated with 22µM FITC labeled HXR9 (green) for two hours and then stained with DAPI (a 
fluorescent dye staining nuclei blue). Scale bar: 5µm (b) IC50 values for HXR9 treatment. The negative 
control peptide CXR9 was not toxic at any of the concentrations tested for any of the cell lines (i.e. the 
IC50 > 100µM). Error bars represent the SEM (n=3), the p values are shown where p<0.01 with respect to 
MCF10a.  
 
Fig. 3 Quantitative PCR and western blotting of TP53 and cFos in HXR9 treated SKBR3 (a) and 
MDA-MB231 (b) cells. RNA and protein was extracted from cells cultured in vitro and treated with 60µM 
peptide for two hours. For QPCR, results are expressed as a ratio with the housekeeping gene GAPDH and 
are the mean of 3 independent experiments, error bars show the SEM. *** p<0.001 with respect to 
untreated cells. The protein levels of cFos and TP53 were also analyzed by western blotting (panel beneath 
graph), using Beta-actin protein as a loading control. 
 
Fig. 4 HXR9 induces apoptosis in SKRB3 cells. SKBR3 cells were treated with 60µM HXR9 or CXR9 
for two hours and cells were assessed for apoptosis or necrosis through Annexin / Propidium iodide 
staining. (a) Example plots for each treatment. (b) The % of cells in early apoptosis (EA), late apoptosis 
(LA), necrosis (N), or which are still viable (V) is shown. (c) Caspase 3 activity in SKBR3 cells treated 
with 60µM HXR9 or CXR9 for two hours. Cells lysates were treated with a Caspase inhibitor (Ac-DEVD-
CHO) to establish background signal (‘-AcDEVD’, ‘+AcDEVD’, lysates untreated / treated with inhibitor). 
Error bars show the SEM. *p<0.05, **p<0.01 with respect to untreated cells 
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Fig. 5 The IC50s for HXR9-treated breast cancer derived cell lines correlate with the mean 
expression of HOX genes HOXB1 through to HOXB9. (a) The mean expression of all HOX genes or (b) 
of HOX genes HOXB1 to HOXB9 were calculated and are shown for each cell line. The cell lines are 
arranged in order of decreasing sensitivity to HXR9 and the IC50 for each cell line is shown below the 
chart. Data are the mean of three independent experiments, error bars show the SEM. * p<0.0073 (applying 
Bonferonni’s correction for multiple hypothesis testing), as compared to SKBR3. P values are not shown 
where p>0.1. NBT – normal breast tissue. (c) Linear regression of cell line IC50s and mean HOX 
expression. The IC50 values for cell killing by HXR9 were plotted against the mean expression level of 
HOX genes HOXB1 through to HOXB9 for each of the cell lines tested. A linear regression (solid line) 
gives an r2 value of 0.9778. The probability for the null hypothesis that the slope of the line is actually zero 
was calculated as to be p = 0.0002. NBT – normal breast tissue. (d) The distribution of mean HOXB1 
through to HOXB9 expression in primary tumors. The expression of these genes in 78 primary tumors (red) 
were plotted according to their theoretical sensitivity to HXR9, as determined using the linear regression 
described above. The regression line shown in part (c) is included for reference. 
 
Fig. 6 HXR9 retards MDA-MB231 tumor growth in vivo. (a) Growth curve for MDA-MB231 tumors 
treated intratumorally with a single dose of HXR9 or CXR9 when the tumor volume reached 100mm3. 
Error bars show the SEM. (b) Survival plot for HXR9 and CXR9 treated tumors shown in (a). (c) 
Expression of cFos in tumors treated with HXR9 or CXR9, shown as a ratio between cFos and GAPDH 
transcripts detected by QPCR. Error bars show the SEM. (d) Section through MDA-MB231 tumors in mice 
treated with CXR9 or HXR9. The CXR9 treated section shows highly undifferentiated tumor cells, whilst 
the HXR9 section shows the remains of dead tumor cells (T) surrounded by stroma (S). Scale bar: 20µm. 
 
Online resource 1 Changes in expression of HXR9 target genes in SKBR3 cells. The relative 
expression of target genes are shown as a normalized intensity value (Log10), blue lines represent targets 
that increase expression in response to HXR9 compared to untreated cells [Unt], whilst the red lines 
represent targets that are repressed by HXR9. 
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Online resource 2 Distribution of HOX/PBX consensus sites in the promoter regions of the 20 most 
responsive HXR9 target genes. Possible HOX / PBX consensus binding sites are shown shaded according 
to the number of nucleotides that match the consensus (out of a maximum of 10). *Multiple consensus sites 
that overlap each other. 
 
Online resource 3 The mean expression values of HOX genes HOXB1 through to HOXB9 in primary 
tumors. Tumors were grouped according to (a) histopathological type, (b) estrogen receptor (ER) status, 
(c) spread to nodes as determined by pathology, (d) 5 year survival, (e) grade (G2, grade 2; G3, grade 3), 
(e) whether tumors were from the left or right breast, (g) progesterone receptor status (PR), and HER2 
status. Error bars show the SEM. 
 
Online resource 4. Summary of breast cancer derived cell lines used in this study. 
 
Online resource 5. Genes with potential tumor suppressor functions that are upregulated by HXR9.  
 
Online resource 6. Summary of pathological data for the primary tumors analyzed in this study. 
 
 
 
 
 
 
